Key facts
- Ambrosia Biosciences shared preclinical data for AMB-702.
- AMB-702 is a novel small molecule GLP-1 receptor agonist.
- Data was presented at the American Diabetes Association's 86th Scientific Sessions.
- Preclinical data indicates superior target coverage and efficacy in lean non-human primates.
Ambrosia Biosciences Inc. has announced preclinical data supporting the differentiated profile of its development candidate, AMB-702. This novel small molecule GLP-1 receptor agonist demonstrated superior target coverage and efficacy in lean non-human primates. The findings were shared as part of a poster presentation at the American Diabetes Association's (ADA) 86th Scientific Sessions, held in Denver, Colorado, on June 5, 2026.